Gene Signal and Collaborators Demonstrate Successful Activity of Topical Aganirsen in Models of Retinal Neovascular Disease  
2/14/2012 7:38:32 AM

LAUSANNE, Switzerland--(BUSINESS WIRE)--Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, today announced the publication of data demonstrating the significant activity of aganirsen (GS-101, eye drops) in two important models of retinal neovascular disease, wet age-related macular degeneration (AMD) and ischemic retinopathy. Gene Signal’s aganirsen is an antisense oligonucleotide that is expected to complete a phase III trial for the treatment of progressive neovascularisation in the cornea in 2012. These data, published online in Investigative Ophthalmology & Visual Science (doi:10.1167/iovs.11-9064), demonstrate the ability of aganirsen to reach and exert activity on the retina.